San Diego-centered Viking Therapeutics marked itself as a significant competitor during the weight loss drug market place in February following revealing promising details from the mid-stage demo of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when given being a weekly injection and in March the com